Vernakalant (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Vernakalant" in English language version.

refsWebsite

Global rank English rank

2europa.eu

68^th place

117^th place

2clinicaltrials.gov

5,225^th place

4,062^nd place

1canada.ca

1,712^th place

1,063^rd place

1medscape.com

719^th place

636^th place

1doi.org

2^nd place

1nih.gov

4^th place

1fiercebiotech.com

low place

8,828^th place

1drugs.com

399^th place

333^rd place

1web.archive.org

1^st place

1merck.com

6,464^th place

5,671^st place

1fda.gov

447^th place

338^th place

1medpagetoday.com

9,274^th place

5,856^th place

canada.ca

"Heart health". Health Canada. 9 May 2018. Retrieved 13 April 2024.

clinicaltrials.gov

Clinical trial number NCT00267930 for "Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence" at ClinicalTrials.gov
Clinical trial number NCT00526136 for "Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study" at ClinicalTrials.gov

doi.org

Finnin M (July 2010). "Vernakalant: A novel agent for the termination of atrial fibrillation". American Journal of Health-System Pharmacy. 67 (14): 1157–64. doi:10.2146/ajhp080501. PMID 20592320.

drugs.com

"FDA Advisory Committee Recommends Approval of Kynapid for Acute Atrial Fibrillation". Drugs.com. Retrieved 15 March 2008.

europa.eu

ema.europa.eu

"Brinavess: EPAR – Product information" (PDF). European Medicines Agency. 19 December 2019.
"Brinavess: EPAR – Public assessment report" (PDF). European Medicines Agency. 25 June 2010.

fda.gov

"December 10, 2019 Meeting of the Cardiovascular and Renal Drugs Advisory Committee Meeting Announcement". FDA. Retrieved 9 December 2019.

fiercebiotech.com

"Merck and Cardiome Pharma Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation". FierceBiotech. 9 April 2009. Retrieved 12 October 2010.

medpagetoday.com

"FDA Panel Shoots Down Afib Cardioversion Drug Over Safety". MedPage Today. Retrieved 11 December 2019.

medscape.com

Finnin M (July 2010). "Vernakalant: A novel agent for the termination of atrial fibrillation". American Journal of Health-System Pharmacy. 67 (14): 1157–64. doi:10.2146/ajhp080501. PMID 20592320.

merck.com

"Brinavess (vernakalant) for Infusion Approved in the European Union for Rapid Conversion of Recent Onset Atrial Fibrillation" (Press release). Merck & Co., Inc. 1 September 2010. Archived from the original on 28 September 2010. Retrieved 28 September 2010.

nih.gov

pubmed.ncbi.nlm.nih.gov

Finnin M (July 2010). "Vernakalant: A novel agent for the termination of atrial fibrillation". American Journal of Health-System Pharmacy. 67 (14): 1157–64. doi:10.2146/ajhp080501. PMID 20592320.

web.archive.org

"Brinavess (vernakalant) for Infusion Approved in the European Union for Rapid Conversion of Recent Onset Atrial Fibrillation" (Press release). Merck & Co., Inc. 1 September 2010. Archived from the original on 28 September 2010. Retrieved 28 September 2010.